Prophylaxis News and Research

RSS

Taiwan residents to receive two month free access to The Cochrane Library

Taiwan residents will receive free access to The Cochrane Library in August and September 2011, in collaboration with the Taiwan Evidence Based Medicine Association at their Annual Conferencein September, whereDr. Charles Young, VP and Publishing Director for Global Clinical Solutions, atThe Cochrane Library's publisher, Wiley-Blackwell, will be presenting a session.

12 Sep 2011

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

9 Sep 2011

Elusys receives federal contract to develop prophylactic treatment against anthrax

Elusys Therapeutics, Inc., a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection.

9 Sep 2011

HRSA announces $5.1M in awards as part of Ryan White HIV/AIDS Program

The Health Resources and Services Administration (HRSA) today announced awards of $5.1 million to provide training and technical assistance (TA) as part of the Ryan White HIV/AIDS Program, which provides HIV-related services in the United States for those who do not have sufficient health care coverage or financial resources for coping with HIV disease.

8 Sep 2011

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Bristol-Myers Squibb Company today announced that new data on NULOJIX (belatacept) will be presented at the European Society for Organ Transplantation (ESOT) Congress on September 4 -7, 2011 in Glasgow, Scotland, United Kingdom.

2 Sep 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

Forum for Collaborative HIV Research discusses PrEP

Following an August 19 meeting convened by the Forum for Collaborative HIV Research to explore recent findings showing the success of pre-exposure prophylaxis (PrEP), "conference participants urged healthcare providers and the public to await further guidance from the CDC and FDA before considering using PrEP. However, if providers believe that initiating PrEP is urgent for a specific patient, CDC recommends following the cautions and procedures previously published for PrEP use in MSM", a Forum press release states.

26 Aug 2011

AHF shares The Lancet's concerns over use of Gilead's Truvada as HIV prevention pill

Today AIDS Healthcare Foundation (AHF) commented on an editorial published in the September 2011 issue of The Lancet Infectious Diseases that raises concerns about the use of the HIV treatment drug Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis (PrEP), agreeing with the publication's public health concerns.

25 Aug 2011

KFDA approves IND for DP-b99 Phase III MACSI stroke study in Korea

D-Pharm Ltd., announced today that the Korean Food & Drug Administration (KFDA) approved the Investigational New Drug application for the Phase III MACSI study of DP-b99 in Korea. The IND has been submitted by D-Pharm's co-development partner in South Korea, Yungjin Pharmaceutical Company Ltd..

24 Aug 2011

$New invasive procedures may help patients with chronic refractory headache$

New invasive procedures may help patients with chronic refractory headache

Cluster headache has a substantial detrimental effect on quality of life. New invasive procedures, such as hypothalamic deep brain stimulation and bilateral occipital nerve stimulation, may help patients with chronic refractory headache.

24 Aug 2011

AHF: Gilead's campaign for FDA approval of Truvada leads to black marketing in Florida

Today AIDS Healthcare Foundation (AHF) decried the fact that the recent campaign by Gilead Sciences Inc. to obtain approval by the U.S. Food & Drug Administration for Truvada as PrEP (pre-exposure prophylaxis) has led to a "black market" for the drug in Florida.

20 Aug 2011

PrEP raises questions regarding 'risk disinhibition' and drug resistance

Nature News reports on "the possibility of unintended public-health consequences" of pre-exposure prophylaxis (PrEP) for HIV and pharmaceutical company Gilead's plan to ask the FDA to evaluate its combination antiretroviral (ARV) drug Truvada for use in healthy people.

18 Aug 2011

Allergan receives positive opinion from Irish Medicines Board for BOTOX

Allergan is pleased to announce that BOTOX has received a positive opinion from the Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity (NDO) resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis.

8 Aug 2011

Hip and knee replacement surgery linked to increased risk of clot development

When tennis star Serena Williams underwent emergency treatment for a pulmonary embolism earlier this year, the world's attention was drawn to this often fatal medical condition which, although surprisingly not uncommon, is unfamiliar to most men and women.

28 Jul 2011

IAS conference concludes with positive news on HIV prevention

"Scientists on Wednesday wrapped up their biggest forum in the 30-year history of AIDS, unveiling stunning weapons to prevent the spread of HIV," Agence France-Presse reports about the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome.

22 Jul 2011

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second quarter of 2010.

19 Jul 2011

UNC receives $3M federal grant for AIDS research

Scientists at the University of North Carolina at Chapel Hill schools of medicine and pharmacy have been awarded a $3 million federal grant to develop and test a new generation of treatments aimed at preventing sexual transmission of HIV to uninfected individuals.

19 Jul 2011

Novel approach for preventing HIV infection

Scientists at Osel Inc. and the National Cancer Institute (NCI) have developed a new way to prevent HIV infection by genetically enhancing the ability of naturally occurring vaginal bacteria to block viral transmission.

19 Jul 2011

Shah congratulates researchers on PrEP findings

In statement released Thursday, USAID Administrator Rajiv Shah said, "I congratulate the Partners PrEP and CDC TDF2 teams on their study findings demonstrating that PrEP (pre-exposure prophylaxis) - and HIV medication when taken orally, once a day - is highly effective in preventing HIV in heterosexual men and women.

16 Jul 2011

Research roundup: Putting good science into practice; shifting hospital costs; finding savings in Mass.

In 2006, researchers published a widely reported study showing that for many patients who had suffered a heart attack more than 24 hours before and had a blocked coronary artery, certain heart procedures, such as balloon angioplasty and the insertion of stents, were no more effective than drugs alone. In 2007, the American Heart Association and the American College of Cardiology issued guidelines urging doctors to not use such treatments in those patients.

16 Jul 2011